Penumbra, Inc. logo

Penumbra, Inc.

PEN

NYSEHealthcareMedical - Devices

Previous close

$325.18

+$1.42 · +0.44%

Aug 21, 4:00 PM ET

PEN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

33

Expensive

Momentum

42

Neutral

Sentiment

47

Mixed

Risk resilience

86

Low Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Adam Elsesser
Listed since
Sep 18, 2015
Employees
4,700

Market position

Day range

Current $325.18

52-week range

Current $325.18

Open
$324.29
Previous close
$323.76
Volume
147.34K
0.36× average
Average volume
404.58K
Average daily volume
Market cap
12.81B USD
Beta
0.7
Market reference 1
50-day average
$320.13
+1.58% above average
200-day average
$321.69
+1.08% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
12.13B USD
P/E (TTM)
79.51×
P/B (TTM)
8.35×
P/S (TTM)
8.51×
EV / EBITDA
54.19×
Earnings yield
1.47%
Free cash flow yield
1.45%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
67.84%
Operating margin
12.45%
Net margin
10.67%
Return on equity
12.45%
Return on assets
9.73%
Return on invested capital
9.88%

Financial health

Debt / equity
0.14×
Current ratio
6.64×
Altman Z-score
19.31
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends74%47%19%-8%Gross margin, FY2021: 63.59%Gross margin, FY2022: 63.18%Gross margin, FY2023: 64.49%Gross margin, FY2024: 63.20%Gross margin, FY2025: 67.14%Operating margin, FY2021: -1.00%Operating margin, FY2022: 0.72%Operating margin, FY2023: 6.95%Operating margin, FY2024: 7.22%Operating margin, FY2025: 13.48%Net margin, FY2021: 0.71%Net margin, FY2022: -0.24%Net margin, FY2023: 8.59%Net margin, FY2024: 1.17%Net margin, FY2025: 12.66%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 63.59%. Gross margin FY2022 63.18%. Gross margin FY2023 64.49%. Gross margin FY2024 63.20%. Gross margin FY2025 67.14%. Operating margin FY2021 -1.00%. Operating margin FY2022 0.72%. Operating margin FY2023 6.95%. Operating margin FY2024 7.22%. Operating margin FY2025 13.48%. Net margin FY2021 0.71%. Net margin FY2022 -0.24%. Net margin FY2023 8.59%. Net margin FY2024 1.17%. Net margin FY2025 12.66%.

Income trends

Revenue

1.4B USD+17.50%

Operating income

189.25M USD+119.49%

Net income

177.69M USD+1168.11%
Income trends across reported periods1.54B USD980.32M USD415.85M USD−148.62M USDRevenue, FY2021: 747.59M USDRevenue, FY2022: 847.13M USDRevenue, FY2023: 1.06B USDRevenue, FY2024: 1.19B USDRevenue, FY2025: 1.4B USDOperating income, FY2021: −7.5M USDOperating income, FY2022: 6.08M USDOperating income, FY2023: 73.55M USDOperating income, FY2024: 86.22M USDOperating income, FY2025: 189.25M USDNet income, FY2021: 5.28M USDNet income, FY2022: −2M USDNet income, FY2023: 90.95M USDNet income, FY2024: 14.01M USDNet income, FY2025: 177.69M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 747.59M USD. Revenue FY2022 847.13M USD. Revenue FY2023 1.06B USD. Revenue FY2024 1.19B USD. Revenue FY2025 1.4B USD. Operating income FY2021 −7.5M USD. Operating income FY2022 6.08M USD. Operating income FY2023 73.55M USD. Operating income FY2024 86.22M USD. Operating income FY2025 189.25M USD. Net income FY2021 5.28M USD. Net income FY2022 −2M USD. Net income FY2023 90.95M USD. Net income FY2024 14.01M USD. Net income FY2025 177.69M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.4B USD1.19B USD1.06B USD847.13M USD747.59M USD
Cost of goods sold461.23M USD439.62M USD375.88M USD311.93M USD272.21M USD
Gross profit942.44M USD755M USD682.64M USD535.21M USD475.38M USD
Research and development89.77M USD94.78M USD84.42M USD79.41M USD104.55M USD
Selling, general, and administrative663.42M USD573.99M USD506.45M USD449.72M USD378.33M USD
Operating expenses753.19M USD668.77M USD609.09M USD529.13M USD482.88M USD
Interest income16.29M USD13.69M USD6.83M USD1.89M USD2.87M USD
Interest expense1.31M USD1.42M USD1.74M USD1.75M USD1.93M USD
Depreciation and amortization17.47M USD23.7M USD27.26M USD24.32M USD16.41M USD
Operating income189.25M USD86.22M USD73.55M USD6.08M USD−7.5M USD
Net income177.69M USD14.01M USD90.95M USD−2M USD5.28M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+4.52%
11 comparable reports
Latest EPS result
0.88
Estimate 1.16 · Miss by 24.14%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.251.040.820.61Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 18, 2025: actual 0.97, estimate 0.88, surprise +10.23%, Beat. Q2 2025, reported Apr 23, 2025: actual 0.83, estimate 0.66, surprise +25.76%, Beat. Q3 2025, reported Jul 29, 2025: actual 0.86, estimate 0.81, surprise +6.17%, Beat. Q4 2025, reported Nov 5, 2025: actual 0.97, estimate 0.929, surprise +4.41%, Beat. Q1 2026, reported Feb 25, 2026: actual 1.18, estimate 1.11, surprise +6.31%, Beat. Q2 2026, reported May 6, 2026: actual 0.82, estimate 1.04, surprise -21.15%, Miss. Q3 2026, reported Jul 30, 2026: actual 0.88, estimate 1.16, surprise -24.14%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate 1.2, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates417.47M376.84M336.21M295.58MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 18, 2025: actual 315.52M USD, estimate 311.63M USD, surprise +1.25%, Beat. Q2 2025, reported Apr 23, 2025: actual 324.14M USD, estimate 327.28M USD, surprise -0.96%, Miss. Q3 2025, reported Jul 29, 2025: actual 339.46M USD, estimate 341.35M USD, surprise -0.55%, Miss. Q4 2025, reported Nov 5, 2025: actual 354.69M USD, estimate 340.95M USD, surprise +4.03%, Beat. Q1 2026, reported Feb 25, 2026: actual 385.39M USD, estimate 361.87M USD, surprise +6.50%, Beat. Q2 2026, reported May 6, 2026: actual 374.76M USD, estimate 370.47M USD, surprise +1.16%, Beat. Q3 2026, reported Jul 30, 2026: actual 390.05M USD, estimate 389.64M USD, surprise +0.10%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 401.41M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

22 ratings
Strong buy00%
Buy941%
Hold1359%
Sell00%
Strong sell00%

PEN news

Corporate actions

Corporate action history

Stock split

Effective Nov 16, 2014

1:10

PEN peers

ETFs holding PEN

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research PEN

research.disclaimer